Notice to readers: Newly licensed smallpox vaccine to replace old smallpox vaccine
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
i

Superseded

This Document Has Been Replaced By:

i

Retired

This Document Has Been Retired

i

Up-to-date Information

This is the latest update:

Notice to readers: Newly licensed smallpox vaccine to replace old smallpox vaccine
  • Published Date:

    February 29, 2008

  • Status:
    current
  • Language:
    English
Filetype[HTM]


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
Details:
  • Description:
    CDC has begun distribution of a new-generation smallpox vaccine, ACAM2000 (Acambis, Inc., Cambridge, Massachusetts), to civilian laboratory personnel, the military, and state public health preparedness programs. ACAM2000 is a live, vaccinia virus smallpox vaccine that was licensed for use in the United States by the Food and Drug Administration in August 2007 (1).* ACAM2000 will be replacing Dryvax smallpox vaccine (Wyeth Pharmaceuticals, Inc., Marietta, Pennsylvania) because of withdrawal of the Dryvax license. ACAM2000 is a live vaccinia virus derived from plaque purification cloning from Dryvax. The safety data available from the ACAM2000 clinical trials indicate a similar safety profile to Dryvax.
  • Document Type:
  • Place as Subject:
  • Main Document Checksum:
  • File Type:
  • Supporting Files:
    No Additional Files
No Related Documents.

You May Also Like: